Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLAR: Pembrolizumab and Olaparib Maintenance in Metastatic Pancreatic Cancer
NCT04666740Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2020
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in pancreatic adenocarcinoma (PDAC), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2020; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04666740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666740.